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Abstract
Background:  Post-mortem Lewy body and Lewy neuritic inclusions are a defining feature of
Parkinson's disease (PD) and dementia with Lewy bodies (DLB). With the discovery of missense
and multiplication mutations in the alpha-synuclein gene (SNCA) in familial parkinsonism, Lewy
inclusions were found to stain intensely with antibodies raised against the protein. Yeast-two-
hybrid studies identified synphilin-1 as an interacting partner of alpha-synuclein, and both proteins
show co-immunolocalization in a subset of Lewy body inclusions. In the present study, we have
investigated whether common variability in synphilin-1, including coding substitutions are genetically
associated with disease pathogenesis.
Methods: We screened the synphilin-1 gene for 11 single nucleotide polymorphisms (SNPs) in 300
affected subjects with idiopathic Parkinson's disease and 412 healthy controls. Six of these were
rare variants including five previously identified amino acid substitutions that were chosen in a
direct approach for association of rare disease causing mutations. An additional five highly
heterozygous SNPs were chosen for an indirect association approach including haplotype analysis,
based on the assumption that any disease causing mutations might be in linkage disequilibrium with
the SNPs selected. We also genotyped a microsatellite marker (D5S2950) within intron 6 of the
gene and five additional microsatellites clustered downstream of the 5p23.1-23.3 synphilin-1 locus.
Genome-wide linkage analysis, in a number of independent studies, has previously highlighted
suggestive linkage to PD in this region of chromosome 5.
Results: Screening of previously known amino acid substitutions in the synphilin-1 gene, identified
the C1861>T (R621C) substitution in four patients (chromosomes n = 600) and 10 control
subjects (chromosomes n = 824), whereas the G2125>C (E706Q) substitution was detected in one
patient and four control subject, suggesting both these substitutions are not associated with
susceptibility to PD. Heterozygous non-synonymous T131>C (V44A) and synonymous C636>T
(P212P) amino acid substitutions were each detected in only one patient with PD. Heterozygous
C1134>T (L378L) synonymous substitutions were found in two patients with PD and one control
subject. D5S2010 the most distal telomeric microsatellite marker genotyped,15.3 Mb from
synphilin-1, was genetically associated with PD (p = 0.006, 27df) independently adjusted for multiple
testing according to its high amount of alleles but not the total number of other markers
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investigated. Other flanking and intronic SNP and microsatellite markers showed no evidence for
genetic association with disease.
Conclusion: In this study rare synphilin-1 SNPs were assessed in a direct association approach to
identify amino acid substitutions that might confer risk of PD in a homozygous or compound
heterozygous state. We found none of these rare variations were associated with disease. In
contrast to prior studies the frequency of the R621C substitution was not significantly different
between PD and control subjects, neither were the V44A or E706Q substitutions. Similarly, our
indirect study of more heterozygous SNPs, including both single marker and haplotype analyses,
showed no significant association to PD. However, marginal association of microsatellite alleles
with idiopathic PD, within the chromosome 5q21 region, indicates further studies are warranted.
Background
Alpha-synuclein is an essential component of Lewy bod-
ies, protein inclusion found post-mortem in affected sub-
jects with synucleinopathies like PD[1], dementia with
Lewy bodies (DLB)[2], and multiple system atrophy
(MSA)[3,4]. Synphilin-1 was identified as an alpha-synu-
clein interacting protein in vitro in a yeast two-hybrid
screen [5], and antibodies of Synphilin-1 have been found
to stain Lewy bodies in brain cells in PD and DLB affected
[6,7]. In a study performed by Wakabayashi and col-
leagues[6], Synphilin-1 was identified in the core of Lewy
bodies with alpha-synuclein situated peripherally, sug-
gesting a possible role of Synphilin-1 protein-protein
interaction in Lewy body formation. Synphilin-1 has also
been implicated in parkinsonism as a protein ubiquinated
by Parkin for which loss of function results in juvenile or
early-onset disease [8,9].
Synphilin-1 has several protein-protein interacting motifs,
including Ankyrin repeats, a coiled coil domain and an
ATP and GTP binding domain [10] (figure 1). By compar-
ing the human and mouse synphilin-1 cDNA sequence it
was confirmed that the regions containing these protein
interacting motifs were among the most conserved
together with a relatively long internal conserved region
[11]. Amino acid substitutions in any of these domains
may impair the protein's function [12].
The region of chromosome 5 in which the synphilin-1
locus resides has been implicated in PD is several inde-
pendent genome wide screens [13-15] although a recent
combined, pooled analysis was not supportive [16]. In
this study we genotyped 11 SNPs in the synphilin-1 gene
using rare variants in a direct association approach and a
group of more informative heterozygous SNPs to assess by
indirect means whether there was any evidence for genetic
association with idiopathic PD. We also screened an inter-
nal microsatellite marker and five additional microsatel-
lites downstream of the synphilin-1 5p23.1-23.3 locus [13-
15].
Methods
PD affected and controls
A total of 305 affected have been clinically examined and
followed longitudinally by one neurologist (JOA) at the
outpatient clinics of three hospitals in Central Norway.
Their diagnosis of PD was based on the presence of two or
more of the cardinal symptoms including tremor, rigidity,
bradykinesia and postural instability, with a positive
response to levodopa, according to Gelb et al. 1999[17].
Five affected subjects did not fulfil the criteria and were
omitted from the association study. They were diagnosed
as PSP (n:2), MSA (n:1), CBD (n:1) and Pick's disease
(n:1). All affected and controls were from Central Nor-
way. The mean age at onset for the PD series was 58.9 ±
11.3 years; the mean age at study was 70.2 ± 10.7 (mean
± SD). Among the PD samples there were 113 females
(37.7%) and 187 males (62.3%). Control subjects
included 412 healthy individuals with age at examination
62.8 ± 10.6 years; (mean ± SD), 171 females (41.5%) and
241 males (58.5%). Four affected were found to have an
additional relative included in the samples. No other fam-
ily relationships were known within the affected samples.
The Ethics Committees (IRB) of Central Norway and
Mayo Clinic Jacksonville approved the study and
informed consent was obtained from all participants.
Marker selection
The strategy for selection of SNPs was bipartite. First, rare
SNPs were selected in a direct approach to identify vari-
ants associated with PD. These included known variants
of low frequency, of which five out of 6 result in non-syn-
onymous or synonymous amino acid substitutions
[10,12]. The low frequency variants were selected through
scrutiny of previously published works by Engelender et al
2000 [10] and Marx et al 2003 [12] that identified some
variants of interest to the study of idiopathic PD in Synphi-
lin-1. Second, using an indirect approach for testing asso-
ciation within haplotype blocks, a group of informative
SNPs (minor allele frequencies > 0.05) were selected from
those available in the National Centre for Biotechnology
Information database [18] (figure 1). In addition, a mic-
rosatellite, D5S2950, within synphilin-1 intron 6 charac-BMC Medical Genetics 2008, 9:19 http://www.biomedcentral.com/1471-2350/9/19
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terized by Engelender and colleagues [10] was genotyped
for association analysis. The selection of additional micro-
satellites, including D5S2115, D5S816, D5S414,
D5S2116 and D5S2010, was based on the heterozygosity
and location downstream of the synphilin-1 locus, span-
ning a region of chromosome 5 previously highlighted in
genome-wide linkage analyses [13-15].
Isolation of DNA and genotype analysis
DNA was isolated from 200 μl whole blood using QIAmp
DNA Blood Mini Kit from Qiagen. All affected and control
subjects were genotyped using SNaPshot® multiplex kit
and a subset confirmed by sequencing using Applied Bio-
systems Bigdye® Terminator V3.1 cycle sequencing kit.
DNA amplification was performed on an Applied Biosys-
tems 2700 PCR machine, according to conditions recom-
mended by the Applied Biosystems SNaPshot® multiplex
kit. Fluorescent SNPs and microsatellite products were
subsequently sized and genotyped on an Applied Biosys-
tems 3100 automated capillary machine. PCR conditions
and primer sequences are available on request.
Statistical analysis
Single marker and haplotype block association were esti-
mated using Haploview version 3.2, estimating statistical
significance by performing 10 000 permutations [19].
Haplotype blocks are defined according to Gabriel et al
[20]. All chromosome marker locations were deduced
from Ensembl gene [ID; ENSG00000064692][21]. Hardy-
Weinberg equilibrium was estimated using PHARE [22].
Multiple marker association for microsatellites was esti-
mated using CLUMP[23]. Differences in allele frequen-
cies, OR, RR and chi-squared p-values were estimated
using the Interactive Statistical Pages [24] by John C. Pez-
zullo PhD, of Georgetown University, Washington DC.
Splice-site predictions of human synphilin-1 exon-intron
sequence were performed using BDGP Splice Site Predic-
tor set [25] for analysis of human sequence.
Results
Using a direct approach, genotyping of known variants in
the synphilin-1gene confirmed the presence of all the 6 var-
iants in affected and/or control subjects (table 1).
The Arg621Cys (R621C)[12] substitution was identified
as heterozygous in four affected and 10 control subjects.
In addition, one of the two patient diagnosed with pro-
gressive supranuclear palsy (PSP) was homozygous for
this relatively rare variant. Subsequent screening of an
additional patient with PSP from the same geographical
region did not reveal the variant. However, all patients
with atypical parkinsonism were omitted from subse-
Organisation of the synphilin-1 gene with motifs as described by Engelender et al 2000 [10] and O'Farrell et al 2002 [11] Figure 1
Organisation of the synphilin-1 gene with motifs as described by Engelender et al 2000 [10] and O'Farrell et al 2002 [11]. The 
SNPs genotyped are located on the figure relative to exons and motifs. Ankyrin-like motifs are highlighted in yellow. The 
coiled-coil motif with ATP and GTP binding domain are marked in green. Motifs involved in interactions with other proteins 
such as alpha-synuclein [29] and Parkin [9, 30] are not known.BMC Medical Genetics 2008, 9:19 http://www.biomedcentral.com/1471-2350/9/19
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quent association analyses (table 1). A heterozygous
Glu709Gln (E706Q) substitution was detected in one
affected patient and four control subjects. A Val44Ala
(V44A) non-synonymous substitution [10] in the first
base of exon 4 was also detected in only one heterozygous
female patient with a diagnosis of 'probable' PD with
onset at 52 years. A synonymous substitution, C636>T,
Pro212Pro[12] was identified in one heterozygous male
patient with a diagnosis of 'atypical' PD, 60 years at onset,
and in no control subjects. The base pair change
C1134>T, leading to another synonymous substitution
Leu378Leu [12] was observed in two patients and one
control subject. A low frequency polymorphism g.IVS6-
62G>A was found in 8 control subjects and 6 patients of
both genders and at equal frequency (table 1).
Highly heterozygous SNPs were used in an indirect asso-
ciation approach and tested for allele and haplotype asso-
ciation with disease. As presented in figure 1, all SNPs are
situated in intronic regions in close proximity to exons.
Single marker association (table 1) and haplotype analy-
ses (table 2) showed no evidence of association between
synphilin-1  and PD. The haplotype block structure
observed (figure 2) corresponded with that identified for
synphilin-1 in the HapMap project, using HapMap version
3.5.
A downstream external microsatellite marker, D5S2010,
showed significant association for PD (p = 0.006, 27 df).
The remaining microsatellite markers, D5S2115, D5S816,
D5S414 and D5S2116 showed no allelic differences when
comparing PD with control subjects or in stratified analy-
ses by diagnostic certainty, age or gender (data not
shown). The microsatellite D5S2950 of synphilin-1
showed no overall association with disease (p = 0.48, 11
df) although some marginal allelic association was
observed.
Discussion
Despite functional research anticipating a role for synphi-
lin-1 in Lewy body disorders, our results, and those of oth-
ers performing association studies on family material and
sporadic populations, do not provide support for a
genetic association between PD and synphilin-1 [26-28].
Our results of rare SNPs were not significant and suggest
that these genetic variants are unlikely to contribute to risk
of PD although it must be noted that some of the SNP fre-
quencies are very low and can not be conclusively
excluded within the limits of the power of these analysis.
A heterozygous intron-exon 4 splice acceptor site non-
synonymous substitution T131>C (V44A), previously
described by Engelender et al 2000[10], was identified in
a female patient with a 'probable' diagnosis of PD, with
onset at 52 years, but was not found to segregate with PD
in her affected brother. The substitution was absent in
control subjects. Thus, while the variant may affect mRNA
splicing it is unlikely to be a major contributor to disease
risk.
Table 1: Genotype frequencies for single markers used in both direct and indirect association analysis obtained with the Haploview 3.2 
software package. P-values and OR are for allelic analysis.
Exon/Intron Nucleotide 
change
Chromosome 
location
Amino acid 
change
Genotypes 
Cases 11/12/22
Controls 11/
12/22
MAF Cases/
controls
Allele 1 vs. 
allele 2 p-value
OR (95% CI)
1g . I V S 1 -
70G>A
121 754 613 ---- 165/115/19 206/176/24 0.26/0.28 0.43 0.90 
[0.71–1.15]
4 T131>C 121 786 462 Val44Ala 296/1/0 405/0/0 0.0/0.0 0.42 ND
4 C636>T 121 786 967 Pro212Pro 296/1/0 405/0/0 0.0/0.0 0.42 ND
5g . I V S 4 -
26G>A
121 788 920 ---- 153/115/32 97/181/34 0.30/0.30 0.91 0.98 
[0.78–1.24]
5 C1134>T 121 789 001 Leu378Leu 295/2/0 404/1/0 0.0/0.0 0.58 2.73 
[0.36–20.9]
6g . I V S 5 + 1 8 8 A
>C
121 789 313 ---- 133/118/42 173/181/53 0.34/0.35 0.78 0.97 
[0.77–1.21]
6g . I V S 5 + 2 3 5 A
>G
121 789 360 ---- 151/115/33 196/183/32 0.30/0.30 0.95 1.01 
[0.80–1.27]
7g . I V S 6 -
62G>A
121 804 161 ---- 291/6/0 397/8/0 0.01/0.01 1.00 1.02 
[0.37–2.84]
7 g.IVS6-23T>C 121 804 200 ---- 154/118/27 202/179/31 0.29/0.29 0.86 0.98 
[0.76–1.23]
10 C1861>T 121 814 302 Arg621Cys 293/4/0† 395/10/0 0.01/0.01 0.42 0.54 
[0.18–1.64]
10 G2125>C 121 814 565 Glu709Gln 296/1/0 401/4/0 0.0/0.0 0.40 0.34 
[0.05–2.27]
†One PSP affected (not accounted for here) was found to be homozygous for this variant. OR-Odds ratio. The SNPs used for indirect analysis were 
highly heterozygous; rs1946649, g.IVS1-70G>A (ObsHet; 0.41); rs2242224, g.IVS4-26G>A (ObsHet; 0.42); rs304383, g.IVS5+188A>C (ObsHet; 
0.43); rs2242223, g.IVS5+235A>G (ObsHet; 0.42) and rs22900987, g.IVS6-23T>C (0.42).BMC Medical Genetics 2008, 9:19 http://www.biomedcentral.com/1471-2350/9/19
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Previously, Marx and colleagues [12] identified the
C1861>T (R621C) substitution in two German patients
with sporadic PD. In our sample from the Norwegian
population, this variation was identified in four patients
with PD (frequency 0.01) and 10 control subjects (fre-
quency 0.02). Rather surprisingly, one patient with PSP
was homozygous for the R621C substitution. However,
PSP is a tauopathy in which synphilin-1 is unlikely to play
a role, and no other PSP patients were identified with the
mutation. Our findings suggest C1861>T (R621C) is only
a polymorphism. The case-control distribution of other
SNPs was approximately equal between groups. No statis-
tical difference was found for single marker or haplotype
block associations, adjusting for age and gender. We
examined five external microsatellite markers, including
D5S816 marker which has previously been implicated in
PD through a genome wide analysis of affected sib-pairs
[14]. In our population there were no significant differ-
ences between affected, controls and diagnosis for any of
the external markers except D5S2010 (p = 0.006) for
Software Haploview version 3.2 were used to estimate haplotype blocks Figure 2
Software Haploview version 3.2 were used to estimate haplotype blocks. Haplotype blocks were defined according to Gabriel 
et al [20].
Table 2: Haplotypes and haplotype frequencies in haploblock 1 as 
defined by default settings using Haploview version 3.2
Haplotype block association
Haplotype Haploblock 1 MAF Chi-square p-value
GAAT Haplotype A 0.35 0.13 0.72
GCAT Haplotype B 0.34 0.18 0.67
AAGC Haplotype C 0.28 0.01 0.93
AAGT Haplotype D 0.02 0.35 0.55
Highly polymorphic markers were used for single marker (table 1) 
and haplotype association analysis. MAF-Minor allele frequency. P-
values calculated using 10 000 permutations.BMC Medical Genetics 2008, 9:19 http://www.biomedcentral.com/1471-2350/9/19
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which neighbouring genetic variability may warrant fur-
ther analysis. Interesting and surprisingly, the D5S2010
marker is more or less directly linked to CENTD3 an effec-
tor of PI3K the gate controller of autophagy, cell survival
and cell death that complexes with SH3KBP1 on Xp22.1-
p21.3.
Conclusion
We found no evidence for association between genetic
variability in synphilin-1 and PD. There were no statistical
differences in allele or genotype frequencies between PD
or control subjects, for common or rare variants within
the synphlin-1 gene. Although synphilin-1 appears to be
present within Lewy bodies, may interact with alpha-
synuclein, and may be a substrate of Parkin, any genetic
evidence for its involvement in disease, either through
sequencing and the identification of rare coding substitu-
tions, association or linkage, is undetected in this Norwe-
gian population study and remains to be confirmed.
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